Ritlecitinib in Patients With Keloids or Those Undergoing Keloidectomy — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Ritlecitinib in Patients With Keloids or Those Undergoing Keloidectomy — Stella

View on ClinicalTrials.gov

Recruiting

Back to Keloid trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

United States

Icahn School of Medicine at Mount Sinai, New York, New York

Key details

Phase

Safety & dosing

Sponsor

Icahn School of Medicine at Mount Sinai

Collaborators

Pfizer

Enrollment target

~30 participants

Started

August 2024

Primary completion

August 2027

Age range

18 Years and older

Last updated September 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.